287 research outputs found

    PROBING EARTH DEFORMATION IN RESPONSE TO LOCALIZED HYDROLOGIC MASS LOADING, SUSITNA RIVER BASIN, ALASKA

    Get PDF
    Surface mass loading contributes a ubiquitous signal to GPS time series that can be modeled and removed for individual sources. We utilize nine GPS stations in the Susitna River watershed, Alaska, to investigate surface displacements from surface mass loading. We find that modeling atmospheric surface pressure and regional hydrologic mass reduces root mean square (RMS) error by 27-39% for all GPS time series. We observe moderate correlation between residual time series pairs and distance, with elevation differences influencing the strength of this correlation. Seasonal horizontal and vertical displacements are observed after removal of all loading models; stations displace downward and northwest during winter months, and upward and southeast during summer months. The temporal displacements are generally correlated with precipitation and Susitna River discharge. Removing the common mode error (CME) from all stations highlights small variations in both spatial and temporal displacements, with time series reflecting local loading sources rather than being dominated by regional trends. The standard deviation of the post-CME measurements indicates that there is moderate uncertainty in both phase and amplitude information. GPS measurement uncertainties contribute to the standard deviation, as well as inter-annual variations in climate; stations also deform due to local variations in temperature and precipitation

    SatCat5: A Low-Power, Mixed-Media Ethernet Network for Smallsats

    Get PDF
    In any satellite, internal bus and payload systems must exchange a variety of command, control, telemetry, and mission-data. In too many cases, the resulting network is an ad-hoc proliferation of complex, dissimilar protocols with incomplete system-to-system connectivity. While standards like CAN, MIL-STD-1553, and SpaceWire mitigate this problem, none can simultaneously solve the need for high throughput and low power consumption. We present a new solution that uses Ethernet framing and addressing to unify a mixed-media network. Low-speed nodes (0.1-10 Mbps) use simple interfaces such as SPI and UART to communicate with extremely low power and minimal complexity. High-speed nodes use so-called ā€œmedia-independentā€ interfaces such as RMII, RGMII, and SGMII to communicate at rates up to 1000 Mbps and enable connection to traditional COTS network equipment. All are interconnected into a single smallsat-area-network using a Layer-2 network switch, with mixed-media support for all these interfaces on a single network. The result is fast, easy, and flexible communication between any two subsystems. SatCat5 is presented as a free and open-source reference implementation of this mixed-media network switch, with power consumption of 0.2-0.7W depending on network activity. Further discussion includes example protocols that can be used on such networks, leveraging IPv4 when suitable but also enabling full-featured communication without the need for a complex protocol stack

    Metabolic requirements for cancer cell proliferation

    Get PDF
    Background: The study of cancer metabolism has been largely dedicated to exploring the hypothesis that oncogenic transformation rewires cellular metabolism to sustain elevated rates of growth and division. Intense examination of tumors and cancer cell lines has confirmed that many cancer-associated metabolic phenotypes allow robust growth and survival; however, little attention has been given to explicitly identifying the biochemical requirements for cell proliferation in a rigorous manner in the context of cancer metabolism. Results: Using a well-studied hybridoma line as a model, we comprehensively and quantitatively enumerate the metabolic requirements for generating new biomass in mammalian cells; this indicated a large biosynthetic requirement for ATP, NADPH, NAD+, acetyl-CoA, and amino acids. Extension of this approach to serine/glycine and glutamine metabolic pathways suggested lower limits on serine and glycine catabolism to supply one-carbon unit synthesis and significant availability of glutamine-derived carbon for biosynthesis resulting from nitrogen demands alone, respectively. We integrated our biomass composition results into a flux balance analysis model, placing upper bounds on mitochondrial NADH oxidation to simulate metformin treatment; these simulations reproduced several empirically observed metabolic phenotypes, including increased reductive isocitrate dehydrogenase flux. Conclusions: Our analysis clarifies the differential needs for central carbon metabolism precursors, glutamine-derived nitrogen, and cofactors such as ATP, NADPH, and NAD+, while also providing justification for various extracellular nutrient uptake behaviors observed in tumors. Collectively, these results demonstrate how stoichiometric considerations alone can successfully predict empirically observed phenotypes and provide insight into biochemical dynamics that underlie responses to metabolic perturbations.National Institutes of Health (U.S.) (Grant 1R01DK075850-01)National Institutes of Health (U.S.) (Grant 1R01CA160458-01A1

    Why Do We Fall? Using Experiences of Failure to Design Case Libraries

    Get PDF
    Instructional designers can support ill-structured problem solving through case libraries that detail domain-specific principles. In this design project, case libraries were employed in an undergraduate sales management course to contextualize knowledge and describe the ill-structured nature of how solutions are derived to solve authentic problems. Whereas many learning environments employ examples of model behavior (Jonassen, 2011), this instructional design was innovative in that the case libraries consisted of sales management failure experiences as the means to facilitate learning. The failure cases embedded within the learning environment engendered design tensions on multiple levels throughout the instructional design. Specifically, this article discusses the issues of engaging the subject matter expert (SME) to talk about failure cases and subsequent challenges to translate the experiences into meaningful learning resources for ill-structured problem solving. Other challenges included how to strategically design the learning environment so that the case library was available at the optimal time for the learners. The design case concludes with a reflection upon the process

    Initial supplementary dose of Dolutegravir in second-line antiretroviral therapy: a noncomparative, double-blind, randomized placebo-controlled trial

    Get PDF
    BACKGROUND: Dolutegravir concentrations are reduced by efavirenz induction effect necessitating twice-daily dolutegravir dosing when coadministered. Efavirenz induction persists for several weeks after stopping, which could potentially select for dolutegravir resistance if switching occurred with unsuppressed human immunodeficiency virus type 1 (HIV-1) RNA levels and standard dolutegravir dosing. We evaluated the need for a lead-in supplementary dolutegravir dose in adults failing first-line tenofovir-emtricitabine-efavirenz (TEE). METHODS: We conducted a randomized, double-blind, placebo-controlled, phase 2 trial in Khayelitsha, South Africa. Eligible patients had virologic failure (2 consecutive HIV-1 RNA ā‰„1000 copies/mL) on first-line TEE. Participants were randomly assigned (1:1) to switch to tenofovir-lamivudine-dolutegravir (TLD) with a supplementary 50 mg dolutegravir dose or placebo taken 12 hours later for 14 days. Primary outcome was proportion with HIV-1 RNA <50 copies/mL at week 24. This study was not powered to compare arms. RESULTS: One hundred thirty participants were randomized (65 to each arm). Median baseline HIV-1 RNA was 4.0 log10 copies/mL and 76% had baseline resistance to both tenofovir and lamivudine. One participant died and 2 were lost to follow-up. At week 24, 55 of 64 (86% [95% confidence interval {CI}: 75%-93%]) in the supplementary dolutegravir arm and 53 of 65 (82% [95% CI: 70%-90%]) in the placebo arm had HIV-1 RNA <50 copies/mL. Grade 3 or 4 adverse events were similar in frequency between arms. None of 6 participants (3 in each arm) eligible for resistance testing by 24 weeks developed dolutegravir resistance. CONCLUSIONS: Our findings do not support the need for initial dolutegravir dose adjustment in patients switching to TLD who failed first-line TEE. CLINICAL TRIALS REGISTRATION: NCT03991013

    Standard-dose versus double-dose dolutegravir in HIV-associated tuberculosis in South Africa (RADIANT-TB): a phase 2, non-comparative, randomised controlled trial

    Get PDF
    Background: The drugā€“drug interaction between rifampicin and dolutegravir can be overcome by supplemental dolutegravir dosing, which is difficult to implement in high-burden settings. We aimed to test whether virological outcomes with standard-dose dolutegravir-based antiretroviral therapy (ART) are acceptable in people with HIV on rifampicin-based antituberculosis therapy. Methods: RADIANT-TB was a phase 2b, randomised, double-blind, non-comparative, placebo-controlled trial at a single site in Khayelitsha, Cape Town, South Africa. Participants were older than 18 years of age, with plasma HIV-1 RNA greater than 1000 copies per mL, CD4 count greater than 100 cells per Ī¼L, ART-naive or first-line ART interrupted, and on rifampicin-based antituberculosis therapy for less than 3 months. By use of permuted block (block size of 6) randomisation, participants were assigned (1:1) to receive either tenofovir disoproxil fumarate, lamivudine, and dolutegravir plus supplemental 50 mg dolutegravir 12 h later or tenofovir disoproxil fumarate, lamivudine, and dolutegravir plus matched placebo 12 h later. Participants received standard antituberculosis therapy (rifampicin, isoniazid, pyrazinamide, and ethambutol for the first 2 months followed by isoniazid and rifampicin for 4 months). The primary outcome was the proportion of participants with virological suppression (HIV-1 RNA <50 copies per mL) at week 24 analysed in the modified intention-to-treat population. This study is registered with ClinicalTrials.gov, NCT03851588. Findings: Between Nov 28, 2019, and July 23, 2021, 108 participants (38 female, median age 35 years [IQR 31ā€“40]) were randomly assigned to supplemental dolutegravir (n=53) or placebo (n=55). Median baseline CD4 count was 188 cells per Ī¼L (IQR 145ā€“316) and median HIV-1 RNA was 5Ā·2 log10 copies per mL (4Ā·6ā€“5Ā·7). At week 24, 43 (83%, 95% CI 70ā€“92) of 52 participants in the supplemental dolutegravir arm and 44 (83%, 95% CI 70ā€“92) of 53 participants in the placebo arm had virological suppression. No treatment-emergent dolutegravir resistance mutations were detected up to week 48 in the 19 participants with study-defined virological failure. Grade 3 and 4 adverse events were similarly distributed between the study arms. The most frequent grade 3 and 4 adverse events were weight loss (4/108 [4%]), insomnia (3/108 [3%]), and pneumonia (3/108 [3%]). Interpretation: Our findings suggest that twice-daily dolutegravir might be unnecessary in people with HIV-associated tuberculosis. Funding: Wellcome Trust
    • ā€¦
    corecore